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A B S T R A C T  
Background: Pseudomonas aeruginosa (P. aeruginosa) is an important bacterial pathogen most frequently associated with 
nosocomial infections, especially in immuno-compromised patients. Early detection of these life threatening, β-lactamase producing 
bacteria is essential for infection control and to prevent their dissemination. The aim of our study was to detect the presence of 
Extended-Spectrum β-Lactamase (ESBL) and Metallo-β-Lactamase (MBL) strains of Pseudomonas aeruginosa. 
Material and Methods: Eighty-eight identified strains of P. aeruginosa were collected from Chughtai Laboratories, Combined 
Military Hospital and Children Hospital, Lahore. These strains were sub-cultured and after confirming the cultural characteristics by 
Gram staining and colony morphology, manual biochemical identification was done. Susceptibility to various antibiotics and 
production of extended-spectrum β-lactamases (ESBLs) and metallo-β-lactamases (MBLs) were determined using modified Kirby 
Bauer disk diffusion method, double disk synergy test, combined disk synergy test (CDST) and inhibitor-potentiated disk diffusion 
test (IPD) respectively. 
Results: Out of eighty-eight strains tested, three were ESBL producers (3.4%) and eleven strains (12.5%) were found to be 
resistant to carbapenems. Of these, eight were MBL producers (72.7%). All these β-lactamase producing strains (14 strains) were 
multidrug-resistant (MDR). Piperacillin and piperacillin/tazobactam proved to be the most effective antibiotics in both types of β-
lactamase producing strains. 
Conclusion: Our study shows noticeable emergence of β-lactamases (ESBLs & MBLs) in P. aeruginosa. All of these strains were 
MDR. It reveals a correlation of these β-lactamases with multidrug resistant genes. 
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I n t r o d u c t i o n  
 
Pseudomonas aeruginosa is an important opportunistic 
pathogen responsible for various healthcare associated 
infections like pneumonia, sepsis, wounds and urinary 
tract infections.1,2 This organism can cause deadly 
infections and is most commonly isolated from wound 
infections in developing countries.3,4 It is professed to be 
associated with high mortality rate i.e. up to 61%.5 
Carbapenems are most effective antibiotics against 
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several pseudomonal infections. However resistance to 
this innovative antibiotic has been observed in recent 
years.6 Metallo β-lactamase is usually associated with 
carbapenems-resistance in P. aeruginosa.7 MBL 
hydrolyzes most of the β-lactam antibiotics except 
monobactams. Additionally, these enzymes are resistant 
to most of the β-lactam inhibitors like clavulanic acid, 
sulbactam.8 Moreover, MBL-producing P. aeruginosa are 
responsible for high a mortality rate.9 
 
Pseudomonal infections are often burdensome because 
of an intrinsic and acquired resistance of the organism to 
common antimicrobials, eventually resulting in emergence 
of multidrug resistant strains of P. aeruginosa.10 Among 
these different resistant mechanisms, β-lactamases 
including Extended-Spectrum β-Lactamases and Metallo 
β-Lactamases are predominantly observed in P. 
aeruginosa.11 ESBL hydrolyzes β-lactam drugs like 
cefotaxime, ceftriaxone, ceftazidime and monobactams 
with no efficacy on cephamycins and carbapenems. β-
lactamase inhibitors like clavulanic acid are effective 
against these enzymes.8,12 
 
The aim of this research was to identify ESBL and MBL-
producing P. aeruginosa and to determine the 
antimicrobial susceptibility patterns of these strains (ESBL 
and MBL producing P. aeruginosa). 
 
M a t e r i a l  a n d  M e t h o d s  
The study was conducted at Department of Microbiology, 
University of Health Sciences, Lahore. This was an 
observational, cross-sectional study conducted over a 
duration of one year from October 2008 to October 2009. 
Eighty-eight strains of P. aeruginosa were collected from 
Chughtai Lahore Laboratories, Combined Military 
Hospital, Lahore and Children Hospital, Lahore, where 
these strains were isolated from wound swabs, pus, 
bronchial washings and blood. Identified strains of P. 
aeruginosa were sub-cultured in Department of 
Microbiology, University of Health Sciences, Lahore. After 
confirming the cultural characteristics by Gram staining 
and colony morphology, manual biochemical identification 
was done  by API 20NE identification system (BioMerieux, 
France). Bio-statistical analysis was done by Pearson’s 
chi-square test as previously used by Giriyapur et al.13  
Antimicrobial susceptibility of P.aeruginosa was 
performed using Mueller-Hinton agar (Oxoid UK), 
according to Clinical Laboratory Standards Institute (CLSI, 
2009) guidelines. Antibiogram profile was generated by 
using: amoxicillin/clavulanic acid (30𝜇g), ceftriaxone 
(30𝜇g), ceftazidime (30𝜇g), ciprofloxacin (5𝜇g), 
sulfamethoxazole/trimethoprim (25𝜇g), piperacillin 
(100𝜇g), piperacillin/tazobactam (100\10𝜇g), aztreonam 
(30𝜇g), meropenem (10𝜇g), imipenem (10𝜇g), and 
amikacin (30𝜇g). Amoxicillin/clavulanic acid was used for 
screening of ESBL producers and 
sulfamethoxazole/trimethoprim (SXT 5𝜇g) were used to 
check whether it is effective in β-lactamase producers 
(Figure 1). 
 
ESBL production in all the isolates was detected by 
double disc synergy test (DDST) as described byJarlier et 
al.14 Synergistic effect of amoxicillin + clavulanic acid (20 
+ 10 μg) was checked with ceftazidime (30 μg) and 
ceftriaxone (30 μg). Strains indicating >5mm synergistic 
zone were confirmed as ESBLproducers.15 
 
MBL production in the carbapenem-resistant isolates was 
detected by following two methods. Pseudomonas 
aeruginosa and Enterobacter cloacae positive for MBL 
were used as positive control. For combination disc test 
(CDST), imipenem (10 µg) and meropenem (10 µg) discs 
(Oxoid) alone and in combination with 0.5 M EDTA were 
used. Increase in the inhibition zone of ≥ 7mm by the 
addition of EDTA indicates MBL-production.16 For Inhibitor 
potentiated disk diffusion test (IPD), imipenem (10 µg) 
(Oxoid) was used along with disc of 0.5 EDTA solution.  
Presence of an augmentation zone (clearing zone) i.e. 
>7mm between EDTA and imipenem discs was 
interpreted as a positive test.17. 
 
R e s u l t s  
Antimicrobial susceptibility pattern of P. aeruginosa 
strains (Table I) showed piperacillin/tazobactam as the 
most sensitive antibiotic with 95.5% susceptible isolates. 
Piperacillin (94.3%) was second most sensitive antibiotic. 
There was no significant difference between these two 
antibiotics. It was followed by meropenem (89.8%), 
imipenem (87.5%), amikacin (84.1%), ceftazidime 
(80.7%), aztreonam (71.6%), and ciprofloxacin (69.3%). 
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Ceftriaxone was least effective among β- lactams with 
only 29.5% susceptible isolates. Amoxicillin/clavulanic 
acid and co-trimoxazole were resistant in all isolates 
(Figure 1). 
 
Figure 1: Antimicrobial resistance pattern of P. aeruginosa strains 
(n=88). Here, AMC =amoxicillin/calvulonic acid, CRO =ceftriaxone, 
CAZ =Ceftazidime, SXT=sulphamethoxazole/trimethoprim, ATM 
aztreonam, AK =Amikacin, CIP = ciprofloxacin, PRL= piperacillin, 
TZP=piperacillin/tazobactam, IPM=imipenem and MEM= 
Meropenem. 
 
 
Figure 2: Demonstration of ESBL phenomenon by Double Disc 
Synergy test (DDST) 
 
 
 
Figure 3: MBL detection tests. A) Combined Disk Synergy Test 
and B) Inhibitor Potentiated Disk Diffusion 
 
 
 
 
n =Total number of strains  
NS=number of sensitive strains 
NR= number of resistant strains 
S (%) = percentage of sensitive strains 
R (%) = percentage of Resistant strains 
 
Table II: Antimicrobial resistance pattern of ESBL and MBL-
producing strains of Pseudomonas aeruginosa 
Sr. 
No 
Antibiotics ENR 
E (%) 
R 
MNR 
M (%) 
R 
1. Co-amoxiclav 3 100 8 100 
2. Ceftriaxone 3 100 8 100 
3. Ceftazidime 3 100 8 100 
4. Cotrimoxazole 3 100 8 100 
5. Ciprofloxacin 3 100 8 100 
6. Piperacillin 0 0.0 0 0.0 
7. Piperacillin/tazobactam 0 0.0 0 0.0 
8. Aztreonam 3 100 6 75 
9. Meropenem 0 0.0 8 100 
10. Imipenem 0 0.0 8 100 
11. Amikacin 2 66.6 8 100 
ENR= number of resistant strains among ESBL producers 
E (%) R = percentageof resistant strains among ESBL producers 
MNR=number of resistant strains among MBL producers 
M (%) R =percentageof resistant strains among MBL producers 
 
Out of 88 cultured isolates of P. aeruginosa three (3.4%) 
were ESBL-producers and eleven strains (12.5%) were 
resistant to carbapenems of which eight (72.7%) were 
MBL-producers. All the ESBL and MBL-producing strains 
were found to be MDR. ESBLs were resistant to β-lactam 
antibiotics except carbapenems where 100% 
susceptibility towards these antibiotics was observed. 
Table: I. Antimicrobial susceptibility pattern of P. aeruginosa 
isolates (n=88) 
Sr. 
No 
Antimicrobials NS S (%) NR R (%) 
1 Co-amoxiclav 0 0 88 100 
2 Ceftriaxone 26 29.5 62 70.5 
3 Ceftazidime 71 80.7 17 19.3 
4 Cotrimoxazole 0 0 88 100 
5 Ciprofloxacin 61 69.3 27 30.7 
6 Piperacillin 83 94.3 5 5.7 
7 Piperacillin/tazobactam 84 95.5 4 4.5 
8 Aztreonam 63 71.6 25 28.4 
9 Meropenem 79 89.8 9 10.2 
10 Imipenem 77 87.5 11 12.5 
11 Amikacin 74 84.1 14 15.9 
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Moreover, ESBLs also indicated high susceptibility 
towards amikacin (Table II). MBL-producers indicated 
100% resistance towards applied antibiotics except 
piperacillin and piperacillin /tazobactam combination 
where 100% sensitivity was observed (Table III). 
 
Table III. Antimicrobial susceptibility pattern of MBL-producing 
and Non-producing Isolates 
 
Antimicrobials 
MBL 
Producing  
(n = 08) 
MBL Non-
producing  
(n = 80) 
X2 
R S S (%) R S S (%) P 
Value 
Co-amoxiclav 8 0 0.0 80 0 0.0 * 
Ceftriaxone 8 0 0.0 54 26 29.5 0.05 
Ceftazidime 8 0 0.0 09 71 80.7 0.00 
Cotrimoxazole 8 0 0.0 80 0 0.0 * 
Ciprofloxacin 8 0 0.0 19 61 69.3 0.00 
Piperacillin 0 8 100 05 75 94.3 0.467 
Piperacillin/ 
tazobactam 
0 8 100 04 76 95.5 0.517 
Aztreonam 6 2 25 19 61 71.6 0.02 
Meropenem 8 0 0.0 01 79 89.8 0.00 
Imipenem 8 0 0.0 03 77 87.5 0.00 
Amikacin 8 0 0.0 06 74 84.1 0.00 
R= Resistant 
S= Sensitive 
* = no statistics is computed as AMC and SXT are constant (Resistant 
in all isolates). 
P value < 0.05 = significant difference 
 
D i s c u s s i o n  
P. aeruginosa is an important nosocomial pathogen, 
endowed with a variety of resistance mechanisms that 
may cause multidrug or even pan-drug resistance. 
Extended-spectrum β-lactamases (ESBLs) and 
carbapenemases (MBLs) are among the most common 
causative agents.18 In the present study, three strains 
(3.5%) were ESBL producers detected by the double disc 
synergy test which is supported by the results of Kotwal et 
al in which 6% of ESBL were detected among cefepime 
resistant P. aeruginos.19,20 While the findings of Wolska 
and Jakubczak, (2008) showed no ESBL detection in P. 
aeruginosa isolates.21 However, it is in contrast to the 
study conducted in Pakistan, where 35.8% strains of 
P.aeruginosa were ESBL-producers.22 This disparity 
might be due to the evidence that more MDRs are 
isolated from burn units.23 
In the present study eleven strains (12.5%) of P. 
aeruginosa indicated resistance to carbapenems of which 
eight were detected as MBL-producers by using the 
CDST and IPD methods. Our data indicates that 
frequency of MBL-producing strains among imipenem 
resistant P. aeruginosa is 72.7%. While Irfan et al 
reported 100% of MBL-production among carbapenem 
resistant P. aeruginosa.24 Our study results are similar to 
the findings of Kali et al where 72.7% MBL-producers 
among carbapenem-resistant P. aeruginosa isolates were 
observed.25 A recent study in Pakistan has described the 
incidence of ESBL and MBL in clinical isolates of MDR P. 
aeruginosa as 23.94% and 40.84% respectively.26  
Our data showed increased resistance to commonly used 
antibiotics. Piperacillin/tazobactam and piperacillin alone 
proved to be effective antibiotics. Carbapenems were 
found to be the second most effective antibiotic group 
accounting for 12.5% and 10.2% resistance for imipenem 
and meropenem respectively, which is consistent with 
national antibiotic resistance data of Pakistan in 2009.27 
 
The β-lactamase-producers were resistant to all other 
antibiotics except the above-mentioned ones, so there 
was a narrow range for a suitable drug of choice. P. 
aeruginosa had shown an increased resistance to the 
fluoroquinolone (30.7%). Resistance rates of amikacin, 
ceftazidime and aztreonam remained 15.9%, 19.3%, 
28.4% respectively and similar reports of 22%, 30% and 
19% resistance have been reported by Pakistan 
Antimicrobial Resistance Network (PARN). Ceftriaxone 
was least effective among β-lactams with only 29.5% 
susceptible isolates. All isolates were resistant to 
amoxicillin/clavulanic acid and co-trimoxazole (as already 
established). These values are comparable to the findings 
available in Pakistan that are 83.8% and 79.24% 
resistance respectively.22 There were 14 (15.9%) isolates 
as MDR, three of these were ESBL and eight out of 
twelve carbapenem resistant isolates were MBL-
producers.  This is an alarming sign as few therapeutic 
options are left for the patients infected with these strains. 
 
Early screening of P. aeruginosa isolates to detect ESBL 
and MBL-production should be emphasized. Therefore, 
routine testing of the isolates of P. aeruginosa for 
sensitivity to ceftazidime, cefotaxime and carbapenems 
may represent a cost-effective way for screening of 
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ESBLs and MBLs. Our study has introduced an easy and 
cost-effective inhibitor potentiated disk diffusion (IPD) 
method for MBL detection in Pakistan. Thus, double disk 
synergy test and combined disk synergy test (CDST) / 
inhibitor-potentiated disk diffusion method (IPD) can 
easily be used to confirm the ESBL and MBL 
phenotypically.  
The emergence of these β-lactamases along with MDR 
genes in P. aeruginosa may adversely muddle the clinical 
management of such patients. High frequency of these 
enzymes urges the infection control teams of hospitals to 
design some preventive measures to stop the 
dissemination of these resistant strains. 
 
C o n c l u s i o n  
Our study shows noticeable emergence of these β-
lactamases in P. aeruginosa. All of these strains were 
MDR. It reveals a correlation of these β-lactamases with 
multidrug resistant genes. 
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